Veterinary Biomarkers Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Animal Type (Companion Animals, Production Animals), By Product Type (Biomarkers, Kits & Reagents, Biomarker Readers), By Application (Disease Diagnostics, Preclinical Research, Others), By Disease Type (Inflammatory & Infectious Diseases, Cardiovascular Diseases, Skeletal Muscle Diseases, Tumor, Others), By Region, & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 1.11 Billion
CAGR (2026-2031)	12.99%
Fastest Growing Segment	Disease Diagnostics
Largest Market	North America
Market Size (2031)	USD 2.31 Billion

Market Overview

The Global Veterinary Biomarkers Market will grow from USD 1.11 Billion in 2025 to USD 2.31 Billion by 2031 at a 12.99% CAGR. Veterinary biomarkers are biological molecules, genes, or characteristics used to indicate normal biological processes, pathogenic transitions, or pharmacologic responses to therapeutic interventions in animals. The market expansion is primarily driven by the escalating prevalence of chronic animal ailments and the rising demand for non-invasive diagnostic precision in veterinary oncology and cardiology. This trajectory is further supported by the substantial growth in the companion animal population, which necessitates specialized health monitoring tools. For instance, according to 'FEDIAF', in '2024', '91 million European households owned at least one pet', underscoring the vast customer base fueling the demand for early disease detection technologies.

Despite these favorable conditions, the market encounters a significant impediment regarding the high costs associated with biomarker validation and commercialization. These financial burdens often translate into expensive diagnostic tests, which can be prohibitive for pet owners and small-scale veterinary practices in developing economies, thereby limiting the widespread adoption of these diagnostic modalities and restraining overall market accessibility.

Key Market Drivers

Substantial growth in veterinary healthcare expenditure significantly accelerates the adoption of advanced biomarker solutions. As pet owners increasingly view their companions as family members, their willingness to invest in premium healthcare services, including complex diagnostic testing for chronic conditions like cancer and cardiac disease, has surged. This financial capability allows veterinary practices to integrate high-cost biomarker assays into routine care, transforming them from niche research tools into essential clinical assets. For instance, according to the American Pet Products Association, June 2025, in the '2024 Dog and Cat Report', total U.S. pet industry expenditures reached $152 billion in 2024, reflecting the massive financial scale supporting this sector. This improved spending power directly funds the commercial viability of novel biomarker panels, ensuring that early disease detection becomes accessible to a broader demographic of animal owners.

Technological advancements in diagnostic biomarker analysis constitute the second major catalyst, enabling rapid and accurate disease profiling at the point of care. Innovations in immunoassay platforms and molecular diagnostics have streamlined the detection of specific biological indicators, allowing veterinarians to make real-time, data-driven treatment decisions without relying solely on external reference laboratories. This shift is evident in the financial performance of industry leaders who are successfully commercializing these technologies. According to Idexx Laboratories, February 2025, in the 'Fourth Quarter and Full Year 2024 Results', the company reported a full-year revenue of $3.898 billion, driven by recurring demand for diagnostic modalities. Furthermore, the market's potential extends beyond North America; according to UK Pet Food, in 2024, 17.2 million households in the United Kingdom owned at least one pet, creating a substantial European customer base for these diagnostic innovations.

Download Free Sample Report

Key Market Challenges

The substantial financial burden associated with biomarker validation and commercialization serves as a primary restraint on the Global Veterinary Biomarkers Market. Manufacturers incur significant expenses during the research and regulatory approval phases, which necessitates high pricing models to ensure return on investment. This cost structure transfers directly to the end-user, resulting in diagnostic tests that are often prohibitively expensive for routine clinical application. Consequently, the adoption of these precise tools is stifled because veterinary practitioners are reluctant to recommend diagnostics that may exceed the financial capabilities of their clients.

This economic friction limits market expansion by confining advanced biomarker usage to affluent demographics or specialized referral centers, rather than becoming a standard of care in general practice. The market struggles to scale when the target consumer base cannot absorb the premium costs. According to the 'American Pet Products Association', in '2024', 'spending on veterinary care and product sales in the U.S. totaled $39.8 billion'. This magnitude of existing expenditure illustrates the heavy financial load already borne by pet owners, creating a challenging environment for introducing additional high-cost diagnostic modalities.

Key Market Trends

The Emergence of Veterinary Liquid Biopsy Solutions is acting as a transformative force in the oncology sector by enabling non-invasive detection of circulating tumor nucleosomes and DNA. This trend addresses the critical market need for simple, accessible screening tools that can identify common cancers, such as lymphoma and hemangiosarcoma, without the complexity of invasive tissue procedures. The commercial adoption of these novel assays is accelerating rapidly as veterinarians integrate them into regular practice for early disease monitoring. For instance, according to VolitionRx Limited, March 2025, in the 'Full Fiscal Year 2024 Financial Results', the company sold approximately 120,000 Nu.Q Vet Cancer Tests in 2024, reflecting a substantial increase in the clinical utilization of blood-based cancer screening methodologies.

Simultaneously, the Expansion of Preventive Wellness and Screening Programs is shifting the market's focus from reactive acute care to proactive health management. Veterinary practices are increasingly bundling biomarker panels into routine wellness visits for asymptomatic pets, aiming to detect sub-clinical renal or cardiac abnormalities before physical symptoms manifest. This strategic pivot is driving higher diagnostic utilization rates per patient visit, independent of illness-related appointments. This growth in proactive testing is evidenced by recent performance metrics; according to Idexx Laboratories, August 2024, in the 'Q2 Fiscal Year 2024 Earnings Call', the diagnostic frequency per wellness visit expanded by 100 basis points year-over-year, underscoring the successful integration of preventive screening protocols into standard veterinary care.

Segmental Insights

The Disease Diagnostics segment is identified as the fastest-growing category in the global veterinary biomarkers market. This expansion is driven by the increasing incidence of infectious and chronic diseases among companion and livestock animals, creating a strong need for early detection. Veterinary professionals are prioritizing biomarker analysis to enhance accuracy in identifying health conditions. Furthermore, guidelines from institutions like the World Organisation for Animal Health regarding disease monitoring encourage the integration of these diagnostic methods. This shift toward preventive healthcare and rapid testing solutions fundamentally supports the accelerated development of the Disease Diagnostics segment.

Regional Insights

North America maintains a leading position in the global veterinary biomarkers market, driven by the high rate of companion animal adoption and increasing expenditure on animal healthcare. The region benefits from established veterinary infrastructure and the concentrated presence of major industry players investing in diagnostic research. Additionally, regulatory frameworks provided by entities like the U.S. Food and Drug Administration facilitate the approval and commercialization of new diagnostic tools. This supportive environment fosters continuous development in disease diagnosis, solidifying North America’s prominence in the sector.

Recent Developments

• In January 2025, IDEXX Laboratories launched the IDEXX Cancer Dx™, a novel blood-based diagnostic panel specifically designed for the early detection of canine lymphoma. This accessible test was made available to veterinarians across North America to be included in routine wellness screenings and diagnostic panels for sick pets. The test is capable of detecting lymphoma before the onset of clinical symptoms, addressing a significant gap in proactive cancer management within the veterinary industry. The President of IDEXX stated that this innovation builds on decades of leadership in diagnostics to redefine cancer detection and monitoring, ultimately supporting better long-term health outcomes for companion animals.
• In July 2024, Ellie Diagnostics entered into a strategic partnership with Heart + Paw, a multi-service pet care company, to enhance veterinary diagnostic services across the latter's network of hospitals. This collaboration integrates the laboratory’s advanced diagnostic services and real-time analytics platform with the partner's pet-centric care model. The alliance aims to elevate the standard of animal health by utilizing data-driven insights for early disease detection and improved patient monitoring. The Chief Executive Officer of Ellie Diagnostics noted that the shared commitment to superior quality care makes the partnership a powerful step forward in transforming the efficiency and effectiveness of veterinary medicine.
• In June 2024, Oxford BioDynamics introduced the EpiSwitch® SCB, a highly accurate and non-invasive blood test engineered to detect six common canine cancers, such as lymphoma, sarcoma, and melanoma. Leveraging the company's proprietary 3D genomic biomarker technology, this diagnostic assay was developed to address the critical need for early and precise disease detection in the veterinary market. The test represents a major advancement in precision medicine for companion animals, allowing veterinarians to identify malignancies before clinical signs become apparent. This development underscores the growing importance of sophisticated biomarker-based assays in improving health outcomes and extending the lives of pets.
• In January 2024, Antech Diagnostics announced the launch of the Nu.Q® Canine Cancer Test, a breakthrough in-hospital diagnostic tool designed to operate on the Element i+® Immunodiagnostic Analyzer. This innovative test utilizes measuring circulating nucleosomes as biomarkers to support the early detection of prevalent canine cancers, including lymphoma and hemangiosarcoma. By providing accurate results in approximately six minutes during routine wellness exams, the test offers a rapid and cost-effective screening solution for veterinary practices. The Chief Medical Officer of Mars Science & Diagnostics described this development as a significant milestone, enabling veterinarians to make more informed clinical decisions at the point of care.

Key Market Players

• Zoetis Inc.
• Virbac SA
• Life Diagnostics Inc
• INGENIUS BIOTECH SL
• Merck & Co., Inc.
• IDEXX Laboratories, Inc.
• Mercodia AB
• Antech Diagnostics Inc

By Animal Type	By Product Type	By Application	By Disease Type	By Region
Companion Animals Production Animals	Biomarkers Kits & Reagents Biomarker Readers	Disease Diagnostics Preclinical Research Others	Inflammatory & Infectious Diseases Cardiovascular Diseases Skeletal Muscle Diseases Tumor Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Veterinary Biomarkers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Veterinary Biomarkers Market, By Animal Type:

• Companion Animals
• Production Animals

• Veterinary Biomarkers Market, By Product Type:

• Biomarkers
• Kits & Reagents
• Biomarker Readers

• Veterinary Biomarkers Market, By Application:

• Disease Diagnostics
• Preclinical Research
• Others

• Veterinary Biomarkers Market, By Disease Type:

• Inflammatory & Infectious Diseases
• Cardiovascular Diseases
• Skeletal Muscle Diseases
• Tumor
• Others

• Veterinary Biomarkers Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE